z-logo
open-access-imgOpen Access
Rapid amplification of prions from variant Creutzfeldt–Jakob disease cerebrospinal fluid
Author(s) -
Barria Marcelo A,
Lee Andrew,
Green Alison JE,
Knight Richard,
Head Mark W
Publication year - 2018
Publication title -
the journal of pathology: clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.849
H-Index - 21
ISSN - 2056-4538
DOI - 10.1002/cjp2.90
Subject(s) - bovine spongiform encephalopathy , prnp , creutzfeldt jakob syndrome , virology , disease , cerebrospinal fluid , medicine , asymptomatic , fatal familial insomnia , prion protein , transmissible spongiform encephalopathy , scrapie , pathology , biology
Human prion diseases constitute a group of infectious and invariably fatal neurodegenerative disorders associated with misfolding of the prion protein. Variant Creutzfeldt–Jakob disease (vCJD) is a zoonotic prion disease linked to oral exposure to the infectious agent that causes bovine spongiform encephalopathy (BSE) in cattle. The most recent case of definite vCJD was heterozygous (MV) at polymorphic codon 129 of the prion protein gene PRNP while all of the previous 177 definite or probable vCJD cases who underwent genetic analysis were methionine homozygous (MM). Retrospective prevalence studies conducted on lympho‐reticular tissue suggest that the number of asymptomatic vCJD carriers in the United Kingdom might be around 1 in 2000 people. In addition, there have been four known cases of the transmission of vCJD infection via blood transfusion. For these reasons, a sensitive, reliable, and fast diagnostic test is currently needed. We describe a rapid and highly sensitive seeding conversion assay that detects disease‐associated prion protein in the brain and cerebrospinal fluid in vCJD after 48–96 h of amplification, with 100% sensitivity and specificity. This method can amplify prions from definite, probable, and possible vCJD cases from patients who are either MM or MV at PRNP ‐codon 129.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here